Q2 FY2026 EarningsQ2 FY2026 results were mixed: revenue beat consensus at $33.7M vs. $31.3M expected, driven by strong $26.2M neffy® product sales. However, EPS miss was significant at -$0.63 vs. -$0.49 expected, due to elevated SG&A costs from legacy consumer marketing. Management pivoted to a targeted provider strategy, guiding to a 40%+ reduction in cash-based SG&A for 2H 2026 and a path to cash flow breakeven by year-end 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: ARS Pharmaceuticals(SPRY) the Revenue is 33.66 M (+114.2%), Beat estimate;the EBIT is -61.47 M (-29.09%), Miss estimate;the EPS is -0.63 (-36.96%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B114.15%
0.03B99.28%
+0.00B14.87%
EBITMiss expectations
-0.06B29.09%
-0.05B11.82%
-0.01B17.27%
EPSMiss expectations
-0.6336.96%
-0.49257.07%
-0.137529.89%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf